Literature DB >> 11260212

Late-onset ornithine transcarbamylase deficiency in two families with different mutations in the same codon.

E Ploechl1, W Ploechl, S Stoeckler-Ipsiroglu, H Pokorny, B Wermuth.   

Abstract

We report on late-onset ornithine transcarbamylase (OTC) deficiency in two families with mutations in the same codon, but different base substitutions. Onset of symptoms showed great variation, and five hemizygotes finally died. Clinical diagnosis was late and difficult. In family A, 1 patient also developed the signs of Gilbert's disease. In family B, the index case came to attention as OTC deficiency, after the transplantation of his liver when the recipient died of cerebral edema and hyperammonemia. In family A, the hemizygote males died at the ages of 12 and 18 years; in family B, they died at the ages of 20, 26, and 30 years, respectively. Diagnosis was confirmed by reduced OTC activity in liver specimens. The residual activity in autopsy liver of the index patient in family A was less than the activity in the biopsy of the transplanted liver of the index patient in family B. The molecular investigations showed mutations in exon 2 at codon 40 in the OTC gene in both families. However, different bases were substituted. In family A, the single-base mutation was a cytosine-to-thymine transition (Arg 40 Cys); in family B, it was a guanine-to-adenine transition (Arg 40 His). Published data on in vitro expression studies of the recurrent OTC mutation Arg 40 His have shown little effect on the protein structure of the enzyme. These studies would fit well with our observation of higher OTC activity and later age of onset of symptoms in family B.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11260212     DOI: 10.1034/j.1399-0004.2001.590208.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  2 in total

1.  Ornithine transcarbamylase deficiency combined with type 1 diabetes mellitus - a challenge in clinical and dietary management.

Authors:  Sarah C Grünert; Pablo Villavicencio-Lorini; Bendicht Wermuth; Willy Lehnert; Jörn Oliver Sass; K Otfried Schwab
Journal:  J Diabetes Metab Disord       Date:  2013-07-05

2.  Common polymorphic OTC variants can act as genetic modifiers of enzymatic activity.

Authors:  Mónica Lopes-Marques; Ana Rita Pacheco; Maria João Peixoto; Ana Rita Cardoso; Catarina Serrano; António Amorim; Maria João Prata; David N Cooper; Luísa Azevedo
Journal:  Hum Mutat       Date:  2021-06-03       Impact factor: 4.878

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.